Plasma tau in Alzheimer disease
Niklas Mattsson,Henrik Zetterberg,Henrik Zetterberg,Henrik Zetterberg,Shorena Janelidze,Philip S. Insel,Ulf Andreasson,Erik Stomrud,Sebastian Palmqvist,David Baker,Cristina Tan Hehir,Andreas Jeromin,David Hanlon,Linan Song,Leslie M. Shaw,John Q. Trojanowski,Michael W. Weiner,Oskar Hansson,Kaj Blennow,Kaj Blennow +19 more
TLDR
Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia, and results do not support plasma tau as an AD biomarker in individual people.Abstract:
Objective: To test whether plasma tau is altered in Alzheimer disease (AD) and whether it is related to changes in cognition, CSF biomarkers of AD pathology (including β-amyloid [Aβ] and tau), brain atrophy, and brain metabolism. Methods: This was a study of plasma tau in prospectively followed patients with AD (n = 179), patients with mild cognitive impairment (n = 195), and cognitive healthy controls (n = 189) from the Alzheimer9s Disease Neuroimaging Initiative (ADNI) and cross-sectionally studied patients with AD (n = 61), mild cognitive impairment (n = 212), and subjective cognitive decline (n = 174) and controls (n = 274) from the Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably (BioFINDER) study at Lund University, Sweden. A total of 1284 participants were studied. Associations were tested between plasma tau and diagnosis, CSF biomarkers, MRI measures, 18 fluorodeoxyglucose-PET, and cognition. Results: Higher plasma tau was associated with AD dementia, higher CSF tau, and lower CSF Aβ 42 , but the correlations were weak and differed between ADNI and BioFINDER. Longitudinal analysis in ADNI showed significant associations between plasma tau and worse cognition, more atrophy, and more hypometabolism during follow-up. Conclusions: Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia. Despite group-level differences, these results do not support plasma tau as an AD biomarker in individual people. Future studies may test longitudinal plasma tau measurements in AD.read more
Citations
More filters
Journal ArticleDOI
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Shorena Janelidze,Niklas Mattsson,Sebastian Palmqvist,Ruben Smith,Thomas G. Beach,Geidy E. Serrano,Xiyun Chai,Nicholas K. Proctor,Udo Eichenlaub,Henrik Zetterberg,Kaj Blennow,Kaj Blennow,Eric M. Reiman,Erik Stomrud,Jeffrey L. Dage,Oskar Hansson +15 more
TL;DR: Plasma P-tau18 level increased with progression of Alzheimer’s disease (AD) and differentiated AD dementia from other neurodegenerative diseases, supporting its further development as a blood-based biomarker for AD.
Journal ArticleDOI
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
TL;DR: Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease and implies a potential usefulness for plasma NFL as a noninvasive biomarker in AD.
Journal ArticleDOI
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
TL;DR: It is proposed that abnormal systemic changes might not only develop secondary to brain dysfunction but might also affect AD progression, suggesting that the interactions between the brain and the periphery have a crucial role in the development and progression of AD.
Journal ArticleDOI
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Sebastian Palmqvist,Shorena Janelidze,Yakeel T. Quiroz,Yakeel T. Quiroz,Henrik Zetterberg,Francisco Lopera,Erik Stomrud,Yi Su,Yinghua Chen,Geidy E. Serrano,Antoine Leuzy,Niklas Mattsson-Carlgren,Olof Strandberg,Ruben Smith,Andrés Villegas,Diego Sepulveda-Falla,Diego Sepulveda-Falla,Xiyun Chai,Nicholas K. Proctor,Thomas G. Beach,Kaj Blennow,Kaj Blennow,Jeffrey L. Dage,Eric M. Reiman,Oskar Hansson +24 more
TL;DR: Plasma P-tau217 levels were significantly greater among PSEN1 mutation carriers, compared with noncarriers, from approximately 25 years and older, which is 20 years prior to estimated onset of MCI among mutation carriers.
Journal ArticleDOI
Biomarkers for Alzheimer's disease: current status and prospects for the future.
Kaj Blennow,Henrik Zetterberg +1 more
TL;DR: Technical developments with ultrasensitive immunoassays and novel mass spectrometry techniques give promise of biomarkers to monitor brain amyloidosis and neurodegeneration in plasma samples and one promising candidate is the synaptic protein neurogranin that seems specific for AD and predicts future rate of cognitive deterioration.
References
More filters
Journal ArticleDOI
Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Guy M. McKhann,David A. Drachman,Marshall F. Folstein,Robert Katzman,Donald L. Price,Emanuel M. Stadlan +5 more
TL;DR: The criteria proposed are intended to serve as a guide for the diagnosis of probable, possible, and definite Alzheimer's disease; these criteria will be revised as more definitive information becomes available.
Book
Statistical Analysis with Missing Data
TL;DR: This work states that maximum Likelihood for General Patterns of Missing Data: Introduction and Theory with Ignorable Nonresponse and large-Sample Inference Based on Maximum Likelihood Estimates is likely to be high.
Journal ArticleDOI
Statistical Analysis with Missing Data
Journal ArticleDOI
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
Clifford R. Jack,Matt A. Bernstein,Nick C. Fox,Paul M. Thompson,Gene E. Alexander,Danielle J Harvey,Bret J. Borowski,Paula J. Britson,Jennifer L. Whitwell,Chadwick P. Ward,Anders M. Dale,Joel P. Felmlee,Jeffrey L. Gunter,Derek L. G. Hill,Ronald J. Killiany,Norbert Schuff,Sabrina Fox-Bosetti,Chen Lin,Colin Studholme,Charles DeCarli,Gunnar Krueger,Heidi A. Ward,Gregory J. Metzger,Katherine T. Scott,Richard Philip Mallozzi,Daniel J. Blezek,Joshua Levy,Josef Phillip Debbins,Adam S. Fleisher,Marilyn S. Albert,Robert C. Green,George Bartzokis,Gary H. Glover,John P. Mugler,Michael W. Weiner +34 more
TL;DR: The approach taken in ADNI to standardization across sites and platforms of the MRI protocol, postacquisition corrections, and phantom‐based monitoring of all scanners could be used as a model for other multisite trials.
Related Papers (5)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura,Naoki Kaneko,Victor L. Villemagne,Takashi Kato,James D. Doecke,Vincent Dore,Christopher Fowler,Qiao-Xin Li,Ralph N. Martins,Christopher C. Rowe,Taisuke Tomita,Katsumi Matsuzaki,Kenji Ishii,Kazunari Ishii,Yutaka Arahata,Shinichi Iwamoto,Kengo Ito,Koichi Tanaka,Colin L. Masters,Katsuhiko Yanagisawa +19 more
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
Guy M. McKhann,Guy M. McKhann,David S. Knopman,Howard Chertkow,Bradley T. Hyman,Clifford R. Jack,Claudia H. Kawas,William E. Klunk,Walter J. Koroshetz,Jennifer J. Manly,Richard Mayeux,Richard C. Mohs,John C. Morris,Martin N. Rossor,Philip Scheltens,Maria C. Carrillo,Bill Thies,Sandra Weintraub,Creighton H. Phelps +18 more